



Patent Application No. 09/974,768
Attorney's Docket No. 033053-040

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Kenneth C. Cundy, et al.) Group Art Unit: 1614
)
Application No.: 09/974,768) Examiner: Unassigned
)
Filed: October 9, 2001)
)
For: Bile-Acid Conjugates for Providing)
Sustained Systemic Concentrations of)
Drugs)
)

TECH CENTER 1600/2900

FEB 13 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

U.S. Patents

<u>Patent No.</u>	<u>Issue Date</u>	<u>Inventor(s)</u>
5,352,682	10/4/94	Sipos
5,462, 933	10/31/95	Kramer, et al.
5,541,348	7/30/96	Arya et al.
5,646,272	7/8/97	Kramer, et al.
5,668,126	9/16/97	Kramer, et al.
5,942,248	8/24/99	Barnwell



0410

0500

Patent

Attorney's Docket No. 033053-040

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 13 2002

TECH CENTER 1600/2900

In re Patent Application of

Kenneth C. Cundy, et al.

Application No.: 09/974,768

Filed: October 9, 2001

For: Bile-Acid Conjugates for Providing
Sustained Systemic Concentrations of
Drugs

Group Art Unit: 1614

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ [x] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By:

Gerald F. Swiss
Registration No. 30,113

Date:

Foreign Patents

<u>Patent No.</u>	<u>Country</u>	<u>Publication Date</u>
0 272 462 B1	Europe	6/29/88

Articles:

Adibi, S.A., "The oligopeptide transporter (Pept-1) in human intestine: Biology and Function", *Gastroenterology*, Vol. 113, pp. 332-340, **1997**.

Baringhaus, K.H., et al., "Substrate specificity of the ileal and hepatic Na⁺ / bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na⁺ / bile acid cotransporter", *J. Lipid Res.*, Vol. 40, pp. 2158-2168, **1999**.

Bryans, J. S., et al., "3-Substituted GABA analogs with central nervous system activity: a review", *Med. Res. Rev.*, Vol. 19, pp. 149-177, **1999**.

Bundgaard, H., in *Design of Prodrugs* (Bundgaard, H. Ed.), Elsevier Science B.V., pp. 1-92, **1985**.

Dieck, S.T., et al., "The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative β -Ala-Lys-N_E-AMCA in astrocytes", *GLIA*, Vol., 25, pp. 10-20, **1999**.

Ho, N. F. H., "Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption", *Ann. N. Y. Acad. Sci.*, Vol. 507, pp. 315-329, **1987**.

Jezyk, N., et al., "Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers", *Pharm. Res.*, Vol. 16, pp. 519-526, **1999**.

Kagedahl, M., et al., "Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity", *Pharm. Res.*, Vol. 14, pp. 176-180, **1997**.

Kim, D.C., "Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides", *J. Drug Targeting*, Vol. 1, pp. 347-359, **1993**.

Kramer, W., et al., "Liver-specific drug targeting by coupling to bile acids", *J. Biol. Chem.*, Vol. 267, pp. 18598-18604, **1992**.

Kramer, W., et al., "Intestinal absorption of peptides by coupling to bile acids", *J. Biol. Chem.*, Vol. 269, pp. 10621-10627, **1994**.

Kramer, W., "Bile acid derived HMG-CoA reductase inhibitors", *Biochim. Biophys. Acta.*, Vol. 1227, pp. 137-154, **1994**.

Kramer, W., et al., "Substrate specificity of the ileal and hepatic Na⁺ / bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters", *J. Lipid Res.*, Vol. 40, pp. 1604-1617, **1999**.

Kullak-Ublick, G.A., et al., "Hepatobiliary transport", *J. Hepatology*, Vol. 32 (Suppl. 1), pp. 3-18, **2000**

Leibach, et al., "Peptide transporters in the intestine and the kidney", *Ann. Rev. Nutr.*, Vol. 16, pp. 99-119, **1996**

Mills, C.O., et al., "Ileal absorption of tyrosine-conjugated bile acids in Wistar rats", *Biochim. Biophys. Acta*, Vol. 926, pp. 154-159, **1987**.

Navia, M.A., "Design principles for orally bioavailable drugs", *Drug Discovery Today*, Vol. 1, pp. 179-189, **1996**.

Petzinger, E., et al., "Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids", *Hepatology*, Vol. 22, pp. 1801-1811, **1995**.

Swaan, P.W., *Use of the intestinal and hepatic bile acid transporters for drug delivery*, Adv. Drug Delivery Rev, **1996**, 20, pp. 59-82.

Swaan, P.W., et al., "Enhanced transepithelial transport of peptides by conjugation to cholic acid", *Bioconj. Chem.*, Vol. 8, pp. 520-525, **1997**.

Tsuji, A., et al., "Carrier-mediated intestinal transport of drugs", *Pharm. Res.*, Vol. 13, pp. 963-977, **1996**.


Wong, et al., "Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain", *Am. J. Physiol.*, Vol. 275, pp. C967-C975, **1998**.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees to Deposit Account No. 02-4800.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Gerald F. Swiss
Registration No. 30,113

Burns, Doane, Swecker & Mathis
P.O. Box 1404
Arlington, VA 22313
Firm Phone: (650) 622-2300

Date: